Market Overview - A-shares experienced a significant afternoon rally, with the Shanghai Composite Index regaining above 3600 points, closing up 0.33% at 3609.71 points, while the ChiNext Index rose nearly 2% to 2406.59 points, marking a new high for the year [1] - The total trading volume in the Shanghai and Shenzhen markets reached 182.96 billion yuan, an increase of approximately 63 billion yuan compared to the previous day [1] Sector Performance - The insurance and banking sectors saw declines, while the semiconductor sector surged, with Dongxin Co. hitting a 20% limit up and Fudan Microelectronics rising nearly 10% [1] - The steel sector also showed strong performance, with Xining Special Steel and Bayi Steel reaching their daily limit up [1] - The innovative drug concept experienced a resurgence, with Sanmiao Gene rising over 20% and several other pharmaceutical stocks hitting their daily limit up [1][3] Notable Stocks - WuXi AppTec reported a 96.20% year-on-year increase in total profit and a 101.92% increase in net profit attributable to shareholders for the first half of the year, with a backlog of orders amounting to 56.69 billion yuan, a 37.2% increase year-on-year [4][5] - The stock of Weiwai New Materials surged over 10 times since July, reaching a new high of 90 yuan per share, although the company cautioned that its stock price has significantly deviated from its fundamental situation [10] Future Outlook - WuXi AppTec expects its revenue from ongoing operations to return to double-digit growth, with an upward adjustment of its overall revenue forecast to between 42.5 billion and 43.5 billion yuan [5] - The innovative drug industry is anticipated to enter a new phase, with significant opportunities expected in 2025, driven by upcoming international conferences and ongoing licensing transactions [6] Semiconductor Sector Insights - The semiconductor sector saw strong gains, with Dongxin Co. and Fudan Microelectronics leading the charge [7] - The U.S. government's recent AI Action Plan aims to bolster domestic semiconductor manufacturing while imposing restrictions on exports, which may accelerate the domestic industry's self-sufficiency [9]

今日（7月29日），A股午后拉升走高，沪指重返3600点上方，创业板指涨近2%站上2400点续创年内新 高；港股走势疲弱，但尾盘跌幅有所收窄。 具体来看，沪指早盘窄幅震荡，午后拉升收复3600点，深证成指、创业板指均大幅走高。截至收盘，沪 指涨0.33%报3609.71点，深证成指涨0.64%报11289.41点，创业板指涨1.86%报2406.59点，科创50指数涨 1.45%，沪深北三市合计成交18296亿元，较此前一日增加约630亿元。 市场走势现明显分化，保险、银行板块下挫；半导体板块拉升，东芯股份20%涨停，复旦微电涨近 10%；钢铁板块再度活跃，西宁特钢（600117）、八一钢铁（600581）涨停；创新药概念再度爆发，三 元基因涨超20%，睿智医药（300149）、辰欣药业（603367）等涨停，药明康德（603259）涨近8%； PCB概念延续强势，方邦股份连续两日涨停；CPO概念崛起，天孚通信（300394）涨近14%，中际旭创 （300308）股价突破200元续创历史新高。值得注意的是，10倍大牛股上纬新材盘中突破90元大关，再 创新高。此外，受传闻提振恒生电子（600570）强势涨停，但 ...

今日（7月29日），A股午后拉升走高，沪指重返3600点上方，创业板指涨近2%站上2400点续创年内新 高；港股走势疲弱，但尾盘跌幅有所收窄。 具体来看，沪指早盘窄幅震荡，午后拉升收复3600点，深证成指、创业板指均大幅走高。截至收盘，沪 指涨0.33%报3609.71点，深证成指涨0.64%报11289.41点，创业板指涨1.86%报2406.59点，科创50指数涨 1.45%，沪深北三市合计成交18296亿元，较此前一日增加约630亿元。 另外，恒瑞医药28日披露，公司与GSK（葛兰素史克）达成协议，将HRS-9821项目的全球独家权利和 至多11个项目的全球独家许可的独家选择权有偿许可给GSK。GSK将向恒瑞支付5亿美元的首付款，如 果所有项目均获得行使选择权且所有里程碑均已实现，恒瑞将有资格获得未来基于成功开发、注册和销 售里程碑付款的潜在总金额约120亿美元。 兴业证券指出，当前我国创新药行业处于3.0时代，从"跟跑者"到"引领者"，2025年成为中国创新药海 外爆品爆发的元年，大量峰值超过30亿—50亿美元的品种浮出水面，对外授权交易不断刷新纪录。预计 今年产业趋势带来的投资机会大于2020—20 ...

题材方面，医疗服务、钢铁行业、化学制药等板块涨幅居前，保险、银行、农牧饲渔等板块跌幅居前。 主力资金上，生物制品、化学制药、半导体等行业概念流入居前。 ETF方面，或受相关消息刺激，创新药、人工智能、5G通信等相关ETF今日表现亮眼！ 2025年7月29日，市场全天震荡拉升，三大指数集体收涨。截至收盘，沪指涨0.33%，深成指涨0.64%， 创业板指涨1.86%。 中信建投证券表示，25Q1创新药、CXO行业持股基金增加明显，多只创新药企获得基金增持，反映出 市场对创新药产业链的持续看好。 相关ETF：港股通创新药ETF(520880)、创新药ETF华泰柏瑞(517120)、创新药ETF天弘(517380)、港股 创新药ETF基金(520700)、创新药ETF富国(159748) 【机构：AI产业链有望持续加速，继续看好AI产业相关投资机遇】 国盛证券表示，本轮人工智能浪潮由DeepSeek等技术创新驱动，有坚实产业价值基础，展示出中国在 AI领域已经具备与全球顶尖水平竞争的实力，这将使全球投资者对中国科技企业的技术创新能力形成 新的认知，进而对中国科技资产重新进行价值评估。 中信证券指出，下一代系统级算力快 ...

Group 1 - The core viewpoint of the articles indicates that the market structure is transitioning from a "barbell strategy" to "mid-assets," with the technology and innovation sectors experiencing cyclical turning points [1] - New growth drivers such as AI (computing power), Hong Kong internet, innovative pharmaceuticals, new consumption, semiconductors, and new energy vehicles are entering their respective cyclical turning points, providing conditions for undervalued large-cap growth and the return of "mid-assets" to excess effectiveness [1] - The ChiNext index currently has a price-to-earnings ratio at the 23.82% percentile over the past decade, showing a significant relative valuation advantage among mainstream broad-based indices, with a first-quarter profit growth rate of 19%, substantially outperforming the overall A-share market's 3.46% [1] Group 2 - The Science and Technology Innovation Board 100 ETF (588120) tracks the Science and Technology Innovation 100 Index (000698), which can have a daily price fluctuation of up to 20% [1] - The index selects medium-sized, liquid listed companies from the Science and Technology Innovation Board, covering high-tech industries such as new-generation information technology, biomedicine, and new materials, reflecting the growth potential of Chinese technology innovation enterprises and overall market performance [1]

福安药业（300194.SZ）7月29日在投资者互动平台表示，长效生长激素研发项目系公司子公司重庆庆余 堂参股公司苏州优诺金公司的在研生物制品项目，该药品属于创新药，但其并非由公司主导进行研发的 项目。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：公司的长效生长激素不属于一类化药吗？一类化药不 就是创新药？ ...

药明康德H股7月以来累计上涨逾42%，年内涨幅超103%，表现更胜A股。 股价大涨背后是公司坚实的业绩表现——药明康德7月28日晚间发布的2025年半年报显示，上半年公司 营收达208亿元，同比增长20.64%；净利润达85.6亿元，同比增长101.92%，创上市以来最佳半年表现； 扣非净利55.82亿元，同比增长26.47%；毛利率提升至44.45%，亦创上市以来半年报数据最高纪录。 靓丽的半年报发布后，多家外资投行就药明康德发布研报上调公司目标价。 转自：新华财经 新华财经上海7月29日电（林郑宏）7月29日，A股三大股指延续涨势，沪指收盘站上3600点整数关口， 收盘点位创年内新高；深成指涨0.64%，创业板指大涨1.86%，自去年11月13日后收盘点位首次突破 2400点整数关口。 医药股成为推动创业板指上涨的主要动力，CXO、减肥药、创新药等概念板块领涨两市，其中CXO板 块涨幅居首。成交额超过10亿元的8只行业主题类ETF中，易方达沪深300医药ETF（512010）上涨 2.68%，成交13.63亿元，位列第4；华宝中证医疗ETF（512170）上涨2.45%，成交11.52亿元，位列第 7。 ...

截至7月29日收盘，创新药概念上涨2.79%，位居概念板块涨幅第3，板块内，195股上涨，睿智医药20% 涨停，奥翔药业、亚太药业、九洲药业等涨停，三元基因、药石科技、南新制药等涨幅居前，分别上涨 20.76%、18.77%、17.01%。跌幅居前的有昂利康、*ST苏吴、多瑞医药等，分别下跌6.16%、5.04%、 4.66%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | CRO概念 | 4.00 | 猪肉 | -1.35 | | 重组蛋白 | 2.90 | 养鸡 | -1.12 | | 创新药 | 2.79 | 草甘膦 | -1.10 | | 减肥药 | 2.76 | 粮食概念 | -1.00 | | F5G概念 | 2.43 | 芬太尼 | -0.88 | | 细胞免疫治疗 | 2.42 | PEEK材料 | -0.85 | | 仿制药一致性评价 | 2.30 | 预制菜 | -0.85 | | 共封装光学(CPO) | 2.23 | 生态农业 | -0.78 | | 特钢概念 | 2.08 | C2 ...

除葛兰外，其他基金经理也对创新药青睐有加。兴证全球基金谢治宇管理的兴全合宜，二季度有 信达生物 、 诺 诚健华 、诺诚健华- U 3只创新药个股进入前十大持仓。谢治宇认为，创新药、智驾汽车、新消费等更具现实业绩 支撑的产业性机会，更适合以机构为主的价值投资者参与。 一些原本不关注医药领域的基金经理也纷纷入场。睿远基金傅鹏博在二季度增加了医药板块配置，涉及创新药等 子行业；永赢基金高楠管理的永赢睿信，在将 康方生物 、百济神州- U买进重仓股后，还在继续加码创新药。 基金二季报显示，创新药板块正成为投资老将们的"心头好"。在政策支持、技术进步、全球合作深化等多重因素 推动下，创新药行业前景广阔，未来有望为投资者带来更多惊喜，市场也将持续关注基金经理们在创新药领域的 后续布局。 以中欧基金葛兰为例，其管理的中欧医疗健康混合A二季度前十大重仓股变动显著， 迈瑞医疗 、 爱尔眼科 等退 出， 百利天恒 、 信立泰 、 百济神州 、 新诺威 4只创新药个股新进。 展望三季度，在创新药领域，中欧基金葛兰在二季报中表示，看好全球合作深化与重要临床数据披露预期。当 前，国内企业在ADC、双抗、多肽等领域的竞争力逐步获得全球认 ...

Core Viewpoint - AstraZeneca has reported strong second-quarter earnings, driven by its innovative cancer drugs, exceeding Wall Street expectations and indicating a positive outlook for the global innovative drug sector [1][2]. Financial Performance - AstraZeneca's total revenue for Q2 increased by 12% year-on-year to $14.5 billion, surpassing Wall Street forecasts [1]. - Adjusted earnings per share for Q2 rose by 10% to $2.17, also exceeding analyst expectations [1]. - For the first half of the year, total revenue grew by 9% to $28 billion, with adjusted earnings per share increasing by 16% to $4.66, both above market expectations [1]. Product Performance - The strong demand for cancer drugs Tagrisso and Imfinzi significantly contributed to AstraZeneca's revenue, with the oncology portfolio generating $6.3 billion in Q2, far exceeding analyst predictions [2][3]. - Tagrisso generated $1.8 billion in revenue for Q2, a 13% year-on-year increase, while Imfinzi brought in $1.5 billion, with a 30% growth [3][5]. Market Strategy - Under CEO Pascal Soriot, AstraZeneca is focusing on oncology and expanding its presence in the U.S. market, committing to invest $50 billion in production and R&D by 2030 [3]. - The company is also developing treatments for cardiovascular diseases and obesity, aiming to create next-generation weight loss drugs [3]. Future Prospects - The upcoming late-stage clinical trial results for the potential blockbuster drug Datroway are expected to be a key catalyst for AstraZeneca's stock performance, although results have been delayed until next year [2][6]. - Datroway is positioned as a new frontline treatment for patients with EGFR-resistant and immune-resistant lung cancer, with a clear commercialization path in non-small cell lung cancer [6].